Intellipharmaceutics Black Owned Emerging Biotech Titan

Dr. Isa Odidi of Intellipharmaceutics is easily one of the sector's genius drug delivery innovators. You’d never notice him if you passed the Nigerian-born CEO on the street. Odidi is a quiet man whose demeanor and smile tend to understate his achievements and brilliance. His work has been cited in textbooks, scientific and medical papers and countless articles, but it was his work at Biovail that caught the attention of Wall Street after he first founded Intellipharmaceutics as a private company with his wife and colleague, Dr. Amina Odidi (an accomplished formulator and scientist who some often refer to as the company's Secret Weapon),  in 1998.

While he was at Biovail, Odidi was performing drug alchemy with formulations that mimicked several hard-to-manufacture generic versions of expensive drugs- among them, Pfizer’s (NYSE:PFE) Procardia XL, Bayer’s (BAYRY.PK) Adalat CC, and Novartis’ (NYSE:NVS) Voltaren XR. While serving as the company’s Vice President of Research of Drug Development and New Technologies he helped grow Biovail through its adolescence.  

As difficult as the scientific process was, the business plan was simple. Odidi and his team worked out the chemical composition to develop the drugs and pushed their versions through the regulatory process at the U.S. Food and Drug Administration. Once approved, the company licensed the drugs to different companies and collected royalties. While Odidi perfected his science and learned to navigate the FDA process, Biovail grew into a 10+billion market cap company.

Intellipharmaceutics has now filed approximately $6 billion of generic controlled released drugs with the FDA to date.

SOURCE: http://biomedreports.com